WebApr 9, 2024 · A minority of patients with follicular lymphoma (FL) undergo histological transformation (HT). This retrospective analysis of 549 patients from the phase 3 GALLIUM study (NCT01332968) assessed the relationship between maximum standardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk. WebDec 4, 2024 · Patient 3: A 67-year-old woman was treated in 2014 for follicular lymphoma grade 1, Ann Arbor stage IV, with 6 cycles of bendamustine and rituximab. She …
FDA approves obinutuzumab for previously untreated follicular lymphoma ...
WebJan 5, 2024 · Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Durig J, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study ... WebOct 5, 2024 · mation from follicular non-Hodgkin’s lymphoma to diffuse large-cell lymphoma according to histo - logic assessment, and minimal residual disease status, … pdf preview in file explorer
Establishing a First-Line Treatment Regimen for …
WebMay 17, 2024 · Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma and the most common indolent B-cell malignancy. The disease often presents in advanced stage and can often be observed before initiation of therapy. Although the incidence is only approximately 15,000 new cases per year, the prevalence is … WebIn GALLIUM (n = 1004; 127 with and 877 without POD24), FLEX increased the intergroup (low-risk/high-risk) difference in 2-year and 3-year PFS rates and demonstrated superior intergroup differences in 2-year and 3-year OS rates … WebNov 13, 2024 · Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: ... The GALLIUM trial enrolled 1202 patients with FL randomized to either receive Rituximab (R)- or Obinutuzumab (GA101, G)-based frontline treatment (Marcus, 2024). The chemotherapy consisted either of CHOP, CVP or Bendamustine … pdf preview in outlook off center